Currency In USD
| Previous Close | 1.1 |
| Open | 1.12 |
| Day High | 1.13 |
| Day Low | 1.06 |
| 52-Week High | 2.73 |
| 52-Week Low | 0.88 |
| Volume | 36,982 |
| Average Volume | 54,887 |
| Market Cap | 10.26M |
| PE | -0.66 |
| EPS | -1.62 |
| Moving Average 50 Days | 1.17 |
| Moving Average 200 Days | 1.59 |
| Change | -0.03 |
IN8bio to Present at TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
GlobeNewswire Inc.
Feb 09, 2026 1:00 PM GMT
Photo Kate Rochlin, Ph.D., President & COO NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
GlobeNewswire Inc.
Feb 03, 2026 1:00 PM GMT
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO an